Cargando…
Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity
Examine Setmelanotide use in patients with rare genetic variants that disrupt the melanocortin pathway. RECENT FINDINGS: Between February 2017 and September 2018, 10 participants with pro-opiomelanocortin (POMC)/ proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency and 11 participants wi...
Autores principales: | Trapp, Christine M., Censani, Marisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973437/ https://www.ncbi.nlm.nih.gov/pubmed/36722447 http://dx.doi.org/10.1097/MED.0000000000000798 |
Ejemplares similares
-
Pediatric Obesity Algorithm: A Practical Approach to Obesity Diagnosis and Management
por: Cuda, Suzanne E., et al.
Publicado: (2019) -
Assessment, differential diagnosis, and initial clinical evaluation of the pediatric patient with obesity: An Obesity Medical Association (OMA) Clinical Practice Statement 2022
por: Cuda, Suzanne E., et al.
Publicado: (2022) -
FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023) -
ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022) -
SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)